Ngm Biopharmaceuticals, Inc.

Yan Wang

Zhonghao Liu

Wenyan Shen

Hugo Matern

Jie Tang

Wenwu Zhai

Yiyuan Yin

Daniel David Kaplan

Dana Yen Mei Duey

Betty Chan Li

Suzanne Christine Crawley

Kalyani Mondal

Jer-Yuan Hsu

Xunshan Ding

Kevin James Paavola

Seth Malmersjö

Vicky Yi-Bing Lin

Allen James Ebens, Jr

Chia-Ying Kao Lam

Geoffrey William Stone

Chun Chu

Jared Martin Higbee

Julie Michelle Roda

Bin Fan

Lee Benjamin Rivera

James Robert Sissons

Jonathan Sitrin

Xuan Zhao

Jr Allen James Ebens

The present disclosure provides binding agents, such as antibodies, that specifically bind ILT2, ILT4, or both ILT2 and ILT4, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

ILT-binding agents and methods of use thereof

The present disclosure provides binding agents, such as antibodies, that specifically bind LAIR-1, including human LAIR-1, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

LAIR-1-binding agents and methods of use thereof

The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

ILT3-binding agents and methods of use thereof

The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.

Binding proteins and methods of use thereof

The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.

C3-binding agents and methods of use thereof

The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.

Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor

The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.

Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof

Anti-C3 antibodies

Antibodies which bind human glucagon receptor

ANGPTL8-binding agents and methods of use thereof

Growing community of inventors

Foster City, CA, United States of America

Yan Wang